Anemic syndrome in patients with rectal cancer
https://doi.org/10.17650/1726-9784-2025-24-3-63-69
Abstract
Background. It is known that anemic syndrome (AS) is often detected in cancer patients during disease diagnosis. AS, along with tumor size and disease stage, is considered as an independent prognostic factor affecting survival.
Aim. To analyze hematological parameters of peripheral blood and ferrokinetic parameters to clarify the role of hepcidin (GP-25), interleukin 6 (IL-6) in early and differential diagnostics of AS variants in patients with rectal cancer (RC).
Materials and methods. The study was conducted in 32 patients with RC before treatment. Hematological parameters of peripheral blood were studied on a Sysmex XE-2100 analyzer (Japan). Determination of the concentration of ferritin, GP-25, IL-6, erythropoietin was performed in blood plasma using ELISA.
Results. Almost half (47 %) of the patients with RC had AS in two variants: iron deficiency anemia and functional iron deficiency (FID). All variants were characterized by microcytosis, hypochromia of erythrocytes and reticulocytes, which indicated iron deficiency erythropoiesis. However, in patients with stages III–IV of the disease and with FID, the concentration of ferritin, GP-25, IL-6, the number of erythrocyte fragmentocytes was statistically significantly higher, and the levels of erythrocytes, hemoglobin, hematocrit were lower than in patients with iron deficiency anemia. This indicated a long-term process of AS formation or anemia of chronic disease with FID. Deviations from the reference value of GP-25 and ferritin levels were detected not only in patients with AS, but also in individual patients without hematological signs of anemia, which did not exclude the latent stage of AS. Erythropoietin deficiency relative to the severity of AS was established in all variants.
Conclusion. The study was small in number, which does not allow us to draw an unambiguous conclusion about the role of GP-25 and IL-6 in the pathogenesis of the AS variant with FJ in patients with RC and requires further study.
About the Authors
Valentina N. Blindar
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Igor A. Klimanov
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424. DOI: 10.3322/caac.21492
2. Ferlay J., Ervik M., Lam F. et al. Global Cancer Observatory: Cancer Today International Agency for Research on Cancer, Lyon, France (2018). URL: https://gco.iarc.fr/today.
3. ЗMalignant neoplasms in Russia in 2020 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2021. 252 p. (In Russ.).
4. Natalucci V., Virgili E., Calcagnoli F. et al. Cancer related anemia: an integrated multitarget approach and lifestyle interventions. Nutrients 2021;13(2):482. DOI: 10.3390/nu13020482
5. Gvirtzman R., Livovsky D.M., Tahover E. et al. Anemia can predict the prognosis of colorectal cancer in the pre-operative stage: a retrospective analysis. World J Surg Onc 2021;19(1):341. DOI: 10.1186/s12957-021-02452-7
6. Yamada T., Endo H., Hasegawa H. et al. Presurgical mild anemia is a risk factor for severe postoperative complications in rectal cancer surgery: a nationwide retrospective cohort study in Japan. Ann Gastroenterol Surg 2024;8(3):471–80. DOI: 10.1002/ags3.12770
7. Deng Yu., Weng M., Zhang J. Preoperative anemia and long-term survival in patients undergoing colorectal cancer surgery: a retrospective cohort study. World J Surg Onc 2023;21(1):122. DOI: 10.1186/s12957-023-03005-w
8. Aapro M., Beguin Y., Bokemeyer C. et al. Management of anemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2018;29(Suppl. 4): iv96–110. DOI: 10.1093/annonc/mdx758
9. Nemeth E., Ganz T. Hepcidin-ferroportin interaction controls systemic iron homeostasis. Int J Mol Sci 2021;22(12):6493. DOI: 10.3390/ijms22126493
10. Wang J., Liu W., Li J.C. et al. Hepcidin downregulation correlates with disease aggressiveness and immune infiltration in liver cancer. Front Oncol 2021;11:714756. DOI: 10.3389/fonc.2021.714756
11. Di Grazia A., Di Fusco D., Franze E. et al. Hepcidin upregulation in colorectal cancer is associated with the accumulation of regulatory macrophages and epithelial-mesenchymal transition and correlates with disease progression. Cancers (Basel) 2022;14(21):5294. DOI: 10.3390/cancers14215294
12. Sasu B.J., Cooke K.S., Arvedson T.L. et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 2010;115(17):3616–24. DOI: 10.1182/blood-2009-09-245977
13. Eskandari F., Dürr M., Buddy K. et al. Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial. Trials 2019;20(1):37. DOI: 10.1186/s13063-018-3158-6
14. Bohlius J., Bohlke K., Castelli R. et al. Management of cancerassociated anemia with erythropoiesis-stimulating agents: ASCO/ ASH clinical practice guideline update. J Clin Oncol 2019;37(15):1336–51. DOI: 10.1200/JCO.18.02142
15. Blindar` V.N., Zubrixina G.N., Klimanov I.A. Endogenous erythropoietin in peripheral blood in patients with colorectal cancer with anemic syndrome. Klinicheskaya laboratornaya diagnostika = Clinical Laboratory Diagnostics 2024;69(3):148–52. (In Russ.). DOI: 10.51620/0869-2084-2024-69-3-148-152
Review
For citations:
Blindar V.N., Klimanov I.A. Anemic syndrome in patients with rectal cancer. Russian Journal of Biotherapy. 2025;24(3):63-69. (In Russ.) https://doi.org/10.17650/1726-9784-2025-24-3-63-69
Views:
59
Email this article 
